Telephone: 81-92-832-1100; Fax: 81-92-832-1102
Original Research: Cancer Stem Cells
Version of Record online: 27 SEP 2011
Copyright © 2011 AlphaMed Press
Volume 29, Issue 10, pages 1485–1495, October 2011
How to Cite
Choijamts, B., Jimi, S., Kondo, T., Naganuma, Y., Matsumoto, T., Kuroki, M., Iwasaki, H. and Emoto, M. (2011), CD133+ Cancer Stem Cell–like Cells Derived from Uterine Carcinosarcoma (Malignant Mixed Müllerian Tumor). STEM CELLS, 29: 1485–1495. doi: 10.1002/stem.711
Author contributions: B.C.: experimental procedures, conception and design, collection and assembly of data, data analysis, manuscript writing; S.J.: collection and assembly of data, data analysis and interpretation; T.K.: conception and design, manuscript writing; Y.N.: collection and assembly of data, data analysis; T.M.: experimental procedures;, M.K.: admistrative support, financial support; H.I.: collection of data, establishment of cell line; M.E.: conception and design, manuscript writing, final approval of manuscript.
Disclosure of potential conflicts of interest is found at the end of this article.
First published online in STEM CELLSEXPRESS September 14, 2011.
- Issue online: 27 SEP 2011
- Version of Record online: 27 SEP 2011
- Accepted manuscript online: 14 SEP 2011 08:48AM EST
- Manuscript Accepted: 9 JUL 2011
- Manuscript Received: 29 APR 2011
- Central Research Institute of Fukuoka University, Fukuoka, Japan. Grant Number: 106001
- Cancer stem cell;
- Uterine carcinosarcoma;
- Malignant mixed Müllerian tumor;
- Müllerian duct
Cancer stem cells (CSCs) that display tumor-initiating properties have recently been identified. CD133, a surface glycoprotein linked to organ-specific stem cells, has been described as a marker of CSCs in different tumor types. We herein identify and characterize CSCs in human uterine carcinosarcoma (malignant mixed Müllerian tumor), which is one of the most aggressive and therapy-resistant gynecological malignancies and is considered to be of mesodermal origin. The CD133+ population was increased in uterine carcinosarcoma, and this population showed biphasic properties in the primary tumor. CD133+ cells predominantly formed spheres in culture and were able to differentiate into mesenchymal lineages. CD133+ cells were more resistant to cisplatin/paclitaxel-induced cytotoxicity in comparison with CD133− cells. A real-time polymerase chain reaction analysis of the genes implicated in stem cell maintenance revealed that CD133+ cells express significantly higher levels of Oct4, Nanog, Sox2, and Bmi1 than CD133− cells. Moreover, CD133+ cells showed a high expression level of Pax2 and Wnt4, which are genes essential for Müllerian duct formation. These CD133+ cells form serially transplantable tumors in vivo and the resulting CD133+ tumors replicated the EpCAM, vimentin, and estrogen and progesterone receptor expression of the parent tumor, indicating that CSCs likely differentiated into cells comprising the uterine carcinosarcoma tissue. Moreover, strong CD133 expression in both epithelial and mesenchymal elements in primary tumor demonstrated significant prognostic value. These findings suggest that CD133+ cells have the characteristics of CSCs and Müllerian mesenchymal progenitors. STEM CELLS 2011;29:1485–1495